Agios Reports Third-Quarter 2026 Financial Results and Business Update
Mitapivat generated worldwide net revenues of $55.4 million in the third quarter.
Story updates
11:43:35 AM UTC
SquawkNews
Agios Pharmaceuticals reported third-quarter 2026 revenue of $55.4 million, up from $12.9 million a year earlier, and a net loss of $65.0 million. The company said U.S. demand for AQVESME continued to expand and it is preparing for a potential mitapivat launch in sickle cell disease. Agios ended th…